Nexalin Technology (NXL) Stock Price, News & Analysis

Company Overview

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Key Stats

• Today's Range: $1.19 to $1.24
• 50-Day Range: $1.19 to $2.48
• 52-Week Range: $0.53 to $4.49
• Volume: 30,782 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $21.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Nexalin Technology Stock Analysis - MarketRank™

Nexalin Technology scored higher than 55% of companies evaluated by MarketBeat, and ranked 161st out of 312 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nexalin Technology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nexalin Technology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nexalin Technology is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nexalin Technology is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nexalin Technology has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.11% of the float of Nexalin Technology has been sold short.

Short Interest Ratio / Days to Cover

Nexalin Technology has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nexalin Technology has recently decreased by 33.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nexalin Technology does not currently pay a dividend.

Dividend Growth

Nexalin Technology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.11% of the float of Nexalin Technology has been sold short.

Short Interest Ratio / Days to Cover

Nexalin Technology has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nexalin Technology has recently decreased by 33.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for NXL on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Nexalin Technology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Nexalin Technology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,200.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

24.00% of the stock of Nexalin Technology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.65% of the stock of Nexalin Technology is held by institutions.

NXL Stock Analysis - Frequently Asked Questions

How have NXL shares performed this year?

Nexalin Technology's stock was trading at $2.76 at the beginning of the year. Since then, NXL shares have decreased by 55.4% and is now trading at $1.23.
View the best growth stocks for 2025 here.

How were Nexalin Technology's earnings last quarter?

Nexalin Technology, Inc. (NASDAQ:NXL) released its earnings results on Tuesday, May, 13th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.05. The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. Nexalin Technology had a negative net margin of 3,407.98% and a negative trailing twelve-month return on equity of 187.59%.

When did Nexalin Technology IPO?

Nexalin Technology (NXL) raised $10 million in an IPO on Friday, September 16th 2022. The company issued 2,315,000 shares at a price of $4.15 per share.

How do I buy shares of Nexalin Technology?

Shares of NXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nexalin Technology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nexalin Technology investors own include Meta Platforms (META), NVIDIA (NVDA), Faraday Future Intelligent Electric (FFIE), Intel (INTC), PayPal (PYPL), Advanced Micro Devices (AMD) and DoorDash (DASH).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NXL
• CIK: 1527352
• Web: www.nexalin.com
• Phone: 832-260-0222
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +306.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,650,000.00
• Net Margins: -3,407.98%
• Pretax Margin: -3,418.41%
• Return on Equity: -187.59%
• Return on Assets: -167.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.42
• Quick Ratio: 15.89

Sales & Book Value

• Annual Sales: $131,065.00
• Price / Sales: 161.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.43 per share
• Price / Book: 2.86

Miscellaneous

• Outstanding Shares: 17,178,000
• Free Float: 10,111,000
• Market Cap: $21.13 million
• Optionable: Not Optionable
• Beta: 4.67